Validation of PSI/PORT, CURB-65 and SCAP scoring system in COVID-19 pneumonia for prediction of disease severity and 14-day mortality

被引:15
作者
Anurag, Aditya [1 ]
Preetam, Mukul [1 ]
机构
[1] Rajendra Inst Med Sci, Dept Gen Med, Boys Hostel 6, Ranchi 834009, Jharkhand, India
关键词
14-day mortality; CAP; COVID-19; pneumonia; CURB-65; criteria; disease severity; PSI/PORT score; SCAP score;
D O I
10.1111/crj.13326
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background: The unprecedented COVID-19 pandemic has put a serious burden on the healthcare system worldwide. Due to varied manifestations of SARS-CoV-2 infection, many scoring systems, which were earlier used for community acquired pneumonia (CAP) are in use to determine the disease severity and the need of ICU admissions for proper management. COVID-19 is a relatively new disease and the validity of these scoring systems in SARS-CoV-2 infection is not completely known. This study aimed to validate these scoring systems in cases of COVID-19 pneumonia in an Indian setup. The study has also tried to find the most accurate indicator of disease severity and 14-day mortality among these scoring systems. Materials and Methods: This study included 122 SARS-CoV-2 infected patients at a tertiary hospital in Ranchi, Jharkhand. The severity of the disease according to ICMR protocol for COVID-19, the PSI/PORT score, the CURB-65 score and the SCAP score were calculated in all the patients and analysed with the disease outcome, that is, 14-day mortality. Results: SCAP score, PSI/PORT score and CURB-65 criteria, all were good indicators of disease severity and 14-day mortality. However, when compared to other scoring systems, SCAP score was a more accurate marker of disease severity and 14-day mortality. Conclusion: The PSI/PORT scoring system, the CURB-65 criteria and the SCAP scoring system can be used to assess the COVID-19 severity and predict the 14-day mortality risk in cases of COVID-19 pneumonia.
引用
收藏
页码:467 / 471
页数:5
相关论文
共 6 条
[1]   Validation of predictive rules and indices of severity for community acquired pneumonia [J].
Ewig, S ;
de Roux, A ;
Bauer, T ;
García, E ;
Mensa, J ;
Niederman, M ;
Torres, A .
THORAX, 2004, 59 (05) :421-427
[2]   A prediction rule to identify low-risk patients with community-acquired pneumonia [J].
Fine, MJ ;
Auble, TE ;
Yealy, DM ;
Hanusa, BH ;
Weissfeld, LA ;
Singer, DE ;
Coley, CM ;
Marrie, TJ ;
Kapoor, WN .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (04) :243-250
[3]  
Fishman, 2015, FISHMANS PULMONARY D, V1, P3952
[4]   Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study [J].
Lim, WS ;
van der Eerden, MM ;
Laing, R ;
Boersma, WG ;
Karalus, N ;
Town, GI ;
Lewis, SA ;
Macfarlane, JT .
THORAX, 2003, 58 (05) :377-382
[5]   COVID-19 Related Coagulopathy: A Distinct Entity? [J].
Marchandot, Benjamin ;
Sattler, Laurent ;
Jesel, Laurence ;
Matsushita, Kensuke ;
Schini-Kerth, Valerie ;
Grunebaum, Lelia ;
Morel, Olivier .
JOURNAL OF CLINICAL MEDICINE, 2020, 9 (06)
[6]   Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention [J].
Wu, Zunyou ;
McGoogan, Jennifer M. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 323 (13) :1239-1242